The Dose

Home

>

The Dose

The Dose

The Dose is Arya Consulting Partners’ newsletter, delivering concise insights on the latest trends, innovations, and market developments shaping the life sciences industry. Each edition curates timely perspectives across biopharma and healthcare, helping industry professionals stay informed on what matters most.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

FDA introduces new approval framework for rare disease therapies

February 6, 2026

The New Calculus: Why Pharma Is Trading Single Assets for Repeatable Engines

November 5, 2025

Novartis accelerates rare-disease and RNA deal spree ahead of major patent cliff

September 12, 2025

From pilots to production: AI becomes priority for pharma leaders

Phase III results support TECENTRIQ chemoimmunotherapy treatment in colon cancer

Amid tariff threats, Roche invests $50 billion to expand US manufacturing

Google launches TxGemma, a collection of open Al models for drug discovery

February 11, 2025

J&J releases promising results from multiple Phase III trials for Darzalex

January 9, 2025

Major pharmaceutical manufacturers plan to overcome the patent expiration cliff

December 6, 2024

Merck presents results across hematology pipeline

November 14, 2024

Amazon plans to expand reach into generic pharmaceuticals with online pharmacy

October 8, 2024

FDA approves first new treatment for schizophrenia in decades

September 14, 2024

Mesopher cell therapy shows 50 increase in 2 year rfs in pancreatic cancer study

August 16, 2024

Xeureka fortanix and nvidia partner to enhance accuracy of ai powered drug discovery

FDA approves lillys kisunla for early symptomatic alzheimers disease

BMS announces positive results for opdivo and yervoy to treat melanoma

AI-Powered patient education evaluating chatgpt 4 0 as a resource for uveitis

FDA warns of t cell malignancies with car t cell therapies

February 16, 2024

FDA approves vertexs casgevy for transfusiondependent beta thalassemia (tdt)

January 13, 2024

Major pharma companies looking to scale back m&a stragegies amid economic downturn

December 1, 2023

FDA investigation of car-t cell therapies

November 1, 2023

Biden signs executive order for a.i. safeguards

October 1, 2023

FDA approves the use of ojjaara (momelotinib) for intermediate/high-risk myelfibrosis in adults

September 1, 2023

FDA approves biomarin's roctavian, the first gene therapy for adults with severe hemophilia a

Following legal battles with abbvie, humira (adalimumab) biosimilars have launched in the u.s.

Eisai and biogen's alzheimer asset, leqembi, recieves fda full approval

New data demonstrate that carvykti reduces risk of disease progression by 74% in multiple myeloma (mm)

Astellas acquires iveric bio for ~$5.9 b

Pfizer demonstrates committment to oncology with $43 billion acquisition of seagen

February 1, 2023

Race disparities in breast cancer treatment and adverse effects among non-hispanic women: a comprehensive analysis

There are no available events matching the current filters.

contact_img

contact_img_mob

contact us

Get In Touch With Us

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Stay Informed with the Latest Insights

Get expert analysis, industry trends, and exclusive updates delivered straight to your inbox. Stay ahead of the curve with valuable insights that drive success.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.